Koncentrated K a Brief Overview:
The Koncentrated K capsule has 25 mg of MK-4, 0.5 mg of MK-7, 5 mg of K1 and 2 mg of Astaxanthin.
Why this combination? We chose one pill to do it all because the K vitamins are a “team” in the body, especially when it is recognized that the A to D to K ratio (developed and championed by the author) is critical to sustain in your body for 24 hrs per day. All K vitamins are similar in structure, but differ in the length of the “side chain”. The longer the side chain, the better effect and efficiency. Consequently, the long chain menaquinones, especially MK-7, are important as they are nearly completely absorbed and stay in the blood for the longest time, and then remain available for tissues outside the liver, namely bones, arteries and soft tissues (organs). Research has also found that Mk7, Mk4 and K1 show up in different tissues within the body, making it important that the Koncentrated K capsule offers the most important K vitamins that research has substantiated as vital to body functioning. When food derived from different forms of phylloquinone and menaquinones were ingested in equal microgram quantities, menaquinones were found to have a concentration 10 times higher than the phylloquinone (Schurgers & Vermeer, 2000). Research also shows that MK-7 has a dramatically longer half-life relative to vitamin K1, so the Koncentrated K supplement provides a more stable bioavailability of K in your body over a 24 to 72 hour period (Schurgers et al., 2007).
Here is what the four natural chemicals look like and as you can easily see, they are in an odd way similar.
Keep it simple - - - (the kiss principle hard at work)!!!!!!!!
Lets keep K1 simple: K1 (phylloquinone) is involved in clotting and bone formation. Basically that is its job. It has “backup” duties, but clotting is #1.
Lets keep Astaxanthin simple: this is a natural product and is the pink in pink salmon, or the pink in rainbow trout, or the pink in pink flamingos. It is also fat soluble, with a chemical structure similar to K. Astaxanthin is carried on your neutraphils and leukocytes, which are both types of white blood cells. Astaxanthin, inhibits the production of MMP-2 and MMP-9 which are chemicals produced by those white blood cells and which tend to induce heart disease (they are chemical irritants to an artery). Thus, Astaxanthin is a potent antioxidant and opponent to those elements which promote atherosclerosis. And Astaxanthin is far superior to C as an antioxidant per the literature. (When one looks at vitamin C, this natural chemical appears to be primarily a virus and bacteria “killer” when taken in sufficient amounts, approximately 6 to 20 grams per day).
Lets keep MK-7 simple: MK-7 is involved with many of the same things as K1 and MK-4 but is unique in that MK-7 “hangs around” your system for 48 to 72 hrs. Why? Most likely to cover for the depletion of K1 and MK-4. A good way to look at MK-7 is that it is the backup to K1 and MK-4, kind of a ready reserve of “K” just in case the others are depleted. The body is just amazing as to the backup systems in place.
Lets keep MK-4 simple: MK-4 is the plough horse of the K vitamins. This chemical is quickly processed and distributed. Why? Most likely because the body is in constant demand for this natural and friendly chemical. So, what are the implications for this plough horse? Research from Canada implicates MK-4 in the prevention of Alzheimer’s. Research from Japan implicates MK-4 as a preventer and reverser of Osteoporosis. Other research indicated the potential for MK-4 to stop, reverse, and then prevent atherosclerosis. MK-4 coupled with Vitamin D and Magnesium, are in theory, a potent “cocktail” that speeds bone healing. Additionally, MK4 is implicated in kidney stone prevention - just to name a few possibilities. The advances in vitamin K analysis of tissues in the body have implicated MK-4 as having particular physiological importance. This vitamer (aka, a natural chemical) is not synthesized in significant amounts by bacteria in the gut and its concentration in nutrients is relatively low. Nonetheless, MK-4 is abundant in tissues such as brain, pancreas, salivary glands, kidney and sternum. (Thijssen and Drittij-Reijnders, 1994: Davidson et al. 1998: Thijssen et al. 1996). This MK-4 tissue distribution is quite distinct from that of the chemically similar vitamins such as phylloquinone (K1). (For example, in rats the tissue concentration ratios of phylloquinone to MK-4 vary from 24:1 in the liver to 0.1:1 in the brain. (Davidson et al, 1998).
So, there you have it. The simple “why” behind Koncentrated K. We encourage you to read the literature contained in this site so as to “get up to speed” with regard to K and how it may impact your life in a positive mode. Again, each component has a role to play and basically they are good and good for you.
Binkley NC, Krueger DC, Engelke JA, Foley AL, Suttie JW. Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr. 2000;72:1523-8.
Binkley NC, et al. A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation. American J of Clin Nutr. 2002;76:1055-60.
Booth SL, Lichtenstein AH, Dallal GE. Phylloquinone absorption from phylloquinone-fortified oil is greater than from a vegetable in younger and older men and women. The J of Nutr. 2002;132:2609-12.
Booth SL. Dietary phylloquinone depletion and repletion in older women. The J of Nutr. 2003;133:2565-69.
Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med. 1994 Dec;17(6):531-9.
Cranenburg EC, Vermeer C, Koos R, Boumans ML, Hackeng TM, Bouwman FG, Kwaijtaal M, Brandenburg VM, Ketteler M, Schurgers LJ. The circulating inactive form of Matrix Gla Protein (ucMGP) as a biomarker for cardiovascular calcification. J Vasc Res. 2008;45(5):427-36.
Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenice, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molbdenum, Nickel, Silicon, Vanadium, and Zinc (2001). Food and Nutrition Board (FNB), Institute of Medicine (IOM). As found online Jan 1 2013 http://www.nap.edu/openbook.php?record_id=10026&page=162
Davidson RT, Foley AL, Engelke JA, Suttie JW. Conversion of dietary phylloquinone to tissue menaquinone-4 in rats is not dependent on gut bacteria. J Nutr. 1998;128:220-3.
Fisher L, Byrnes E, and Fisher AA. Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. Nutr Res. 2009 Sep;29(9):676-83. 2009.
Garber, AK, Binkley NC, Krueger DC, Suttie JW. Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects. Journal of Nutr. 1999;129:1201–03.
Gijsbers BLMG, Siong K, Vermeer C. Effect of food composition on vitamin K absorption in human volunteers. British J of Nutri. 1996;76:223-229.
Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Min Res 1993;8:1241-45.
Huyghebaert N, De Beer J, Vervaet C, Remon, JP. Compounding of vitamin A, D3, E and K3 supplements for cystic fibrosis patients: formulation and stability study. 2007 Oct;32(5):489-96.
Institute of Medicine at the National Academy of sciences. Updated 2001. URL. http://www.iom.edu/Object.File/Master?54/411/DRIs.Vitamins.pdf.
Jie KS, Hamulyak K, Gijsbers BL, Roumen FJ, Vermeer C. Serum osteocalcin as a marker for vitamin K-status in pregnant women and their newborn babies. Thromb Haemost. 1992 Oct 5;68(4):388-91.
Jie KG, Bots ML, Vermeer C, Witteman JC, Grobbee DE.Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int. 1996 Nov;59(5):352-6
Knapen HM, Jie KS, Hamulyak K, Vermeer C. Vitamin K-induced changes in markers for osteoblast activity and urinary calcium loss. Calcif Tissue Int. 1993 Aug;53(2):81-5.
Kohlmeier M, Salomon A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. The J of Nutr. 1996;126:1192S-1196.
Kuwabara A, Tanaka K, Tsugawa N et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos Int. 2009 Jun;20(6):935-42.
Lamon-Fava S, Sadowski J, Davidson K, O’Brien M, McNamara J, Schaefer E. Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am J Clin Nutr. 1998;67:1226-31.
Lamson DW, Plaza SM. The anticancer effects of vitamin K. Altern Med Rev 2003 Aug;8(3):303-18.
Mager DR, McGee PL, Furuya KN et al. Prevalence of vitamin K deficiency in children with mild to moderate chronic liver disease. J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):71-6.
McCann JC, Ames BN. Vitamin K, an example of triage theory: Is micronutrient inadequacy linked to diseases of aging. Am J Clin Nutr. 2009 Oct;90(4):889-907.
Plantalech L, Guillaumont M, Vergnaud P, Leclercq M, Delmas PD. Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J Bone Miner Res. 1991;6(11):1211-6.
Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012 Nov 12;11:93.
Schoon EJ, Müller CA, Vermeer C, Schurgers LJ, Brummer R-J M, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn’s disease: Another pathogenetic factor of osteoporosis in Crohn’s disease? Gut 2001;48:473–77.
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis. 2000;30:298-307.
Schurgers LJ, Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochimica et Biophysica Acta. 2002;1570:27-32.
Schurgers LJ, Teunissen KJ, Hamulyak K, Knapen MH, Vik H, Vermeer C. Vitamin K-containing dietary supplements: Comparison of synthetic vitamin K1 and natto-derived menaquinone-7. Blood. 2007;109:3279-83.
Shearer MJ, McBurney A, Barkhan P. Effect of warfarin anticoagulation on vitamin-K 1 metabolism in man. Br J Haematol. 1973 Apr;24(4):471–79.
Sokoll LJ, et al. Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. American Journal of Clinical Nutrition. 1997;65:779-784.
Suttie JW. Warfarin and vitamin K. Clin Cardiol. 1990;13:16-18.
Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr. 1995;15:399-417.
Thijssen HH, Drittij-Reijnders MJ. Vitamin K distribution in rate tissues: Dietary phylloquinone is a source of tissue menaquinone-4. Br J Nutr. 1994;72:415-25.
Thijssen HHW, Drittij-Reijnders MJ. Tissue distribution of vitamin K: Vitamin K distribution in rate tissues: Phylloquinone is a source of tissue menaqinone-4. British J of Nutr. 1994 Sept;72 (3):415-25.
Thijssen HHW, Drittij-Reijnders MJ, Fischer MA. Phylloquinone and menaquinone-4 distribution in rats: Synthesis rather than uptake determines menaquinone-4 organ concentrations. J Nutr. 1996;126:537-43.
Thijssen HHW, Drittij M-J, Vermeer C, Schoffelen E. Menaquinone-4 in breast milk is derived from dietary phylloquinone. British Journal of Nutrition. 2002;87:219–26.
Thujssen HHW, Drittij-Reijnders MJ, Fischer MA. Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations. J Nutr. 1996 Feb;126(2):537-43.
Uematsu T, et al. Effect of dietary fat content on oral bioavailability of menatetrenone in humans. Journal of Pharmaceutical Sciences. 1996;85:1012-16.
van Summeren M, Braam L, Noirt F, Kuis W, Vermeer C. Pronounced elevation of undercarboxylated osteocalcin in healthy children. Pediatr Res. 2007;61(3):366-70.
Vermeer C, Shearer MJ, Zittermann A, Bolton-Smith C, Szulc P, Hodges S, Walter P, Rambeck W, Stöcklin E, Weber P. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Nutr. 2004 Dec;43(6):325-35. Epub 2004 Feb 5.
Vermeer C. Vitamin K: the effect on health beyond coagulation – an overview. Food Nutr Res. 2012; 56:10.3402